Weekly Digest – October 2026 Weekly Digest – October 2026 25 September 2026: Perioperative Imfinzi plus Enfortumab vedotin received U.S. FDA Priority Review for MIBC AstraZeneca announced that the U.S. FDA has accepted supplemental Biologics License Application for Imfinzi in […]
Weekly Digest – October 2026 Weekly Digest – October 2026 28 September 2026: BL-M05D1 received BTD in China for previously treated advanced Gastric/GEJ cancer Biokin Pharma announced that BL-M05D1, its Claudin18.2-directed ADC, has been included in China’s NMPA Breakthrough Therapy […]
Weekly Digest – October 2026 Weekly Digest – October 2026 25 September 2026: Ifinatamab deruxtecan BLA for previously treated extensive-stage SCLC was voluntarily withdrawn in the U.S. Daiichi Sankyo and MSD announced the voluntary withdrawal of the U.S. BLA seeking […]
Weekly Digest – October 2026 Weekly Digest – October 2026 28 September 2026: AstraZeneca announced an equity investment and clinical collaboration with Summit Therapeutics to advance ADC combinations in cancer AstraZeneca announced a US$2 billion strategic equity investment in Summit […]
Weekly Digest – October 2026 Weekly Digest – October 2026 29 September 2026: Nurix Therapeutics announced a $7 million milestone achievement under its strategic collaboration with Pfizer Nurix Therapeutics announced the achievement of a US$7 million research milestone under its […]
Weekly Digest – October 2026 Weekly Digest – October 2026 01 October 2026: Dong-A ST and Galux entered a research collaboration to develop AI-designed antibodies for ADC therapeutics Dong-A ST and Galux announced a research collaboration to develop novel ADC […]
Weekly Digest – September 2026 Weekly Digest – September 2026 18 September 2026: Enhertu receives CHMP recommendation for adjuvant treatment of HER2-positive early Breast cancer Daiichi Sankyo and AstraZeneca announced that Enhertu has been recommended by the EMA’s CHMP for […]
Weekly Digest – September 2026 Weekly Digest – September 2026 18 September 2026: PADCEV + Keytruda receives positive CHMP opinion for resectable MIBC Astellas and MSD announced that PADCEV in combination with KEYTRUDA received a positive CHMP opinion for perioperative […]
Weekly Digest – September 2026 Weekly Digest – September 2026 23 September 2026: SOTIO advances SOT106 with dual FDA designations for Sarcoma SOTIO announced that SOT106 received two additional FDA designations: Orphan Drug Designation for soft tissue sarcoma and Fast […]
Weekly Digest – September 2026 Weekly Digest – September 2026 22 September 2026: Iza-bren granted BTD in China for the treatment of mTNBC Biokin announced that Iza-bren, its first-in-class EGFR×HER3 bispecific ADC, has received China NMPA Breakthrough Therapy Designation for […]
